Previous Pause Next
Home >> News Center >> Investment & Financials >>
Investment & Financials
Glaxo Joins J&J in $200 Million Fund With Index Ventures PDF Print E-mail
Thursday, 22 March 2012 07:21

GlaxoSmithKline Plc (GSK) and Johnson & Johnson (JNJ) are forming a $200 million fund with Index Ventures to invest in early-stage biotechnology companies, a move that may entice venture capitalists back to the industry.

Marina Biotech, Inc. Announces a $15 Million Purchase Agreement With Lincoln Park Capital Fund, LLC PDF Print E-mail
Thursday, 20 October 2011 00:34
Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor, whereby LPC has committed to invest, at the Company's sole option, up to $15 million of equity capital.
Acino Holding Ltd to Buy Cephalon, Inc. Units For EU 80 Million Cash, Shares PDF Print E-mail
Thursday, 20 October 2011 00:26
Acino and Cephalon Inc. has entered into an agreement under which Acino will acquire Cephalon's combined Middle East and African business for a total consideration of approximately 80 million euros.
Sofinnova Ventures Raises $440 Million for Biotech-Only VC Fund PDF Print E-mail
Wednesday, 19 October 2011 00:14
Amid the doom and gloom of venture investing in biotech, Sofinnova Ventures said Monday that it has raised a $440 million life sciences-focused fund.
Epizyme Wins $4 Million Milestone Payments From GlaxoSmithKline (GSK) Deal PDF Print E-mail
Tuesday, 18 October 2011 00:56

Cambridge-based Epizyme Inc. will be getting a $4 million milestone payment from its collaboration partner GlaxoSmithKline (GSK) now that it has reached a certain pre-clinical stage in the development of potential enzyme-based cancer treatments.

Capstone Therapeutics Announces Plan to Preserve Cash During Ongoing Partnering Efforts, Cutting Staff Down to 4 PDF Print E-mail
Tuesday, 18 October 2011 00:42
Capstone Therapeutics (Nasdaq:CAPS) (the "Company") announced today its plan to preserve cash during ongoing discussions with potential partners regarding AZX100 in dermal scarring. The Company will reduce staff from its current 18 full-time employees to a core of four individuals covering required regulatory and financial functions at substantially reduced compensation.
MediciNova, Inc. to Receive $2.5 Million Payment From Kissei Pharmaceutical Co., Ltd. to Expand Clinical Development of the MN-221 Program PDF Print E-mail
Monday, 17 October 2011 00:00
MediciNova Inc., a biopharmaceutical company publicly traded on the NASDAQ Global Market (Nasdaq:MNOV - News) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced that Kissei Pharmaceutical Co. Ltd., a pharmaceutical company traded on the Tokyo Stock Exchange (4547), will pay MediciNova $2.5 million, within 30 days, to support further clinical development of MN-221 for the treatment of acute exacerbations of asthma or chronic obstructive pulmonary disease (COPD).
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies PDF Print E-mail
Saturday, 15 October 2011 00:45
Cleave Biosciences, a newly established biopharmaceutical company discovering and developing novel therapies for cancer, announced today it has raised $42 million in Series A financing. Cleave Biosciences was established by Scientific Co-Founders Raymond Deshaies, Ph.D., Seth Cohen, Ph.D. and Francesco Parlati, Ph.D.
DNAnexus, Inc. Secures $15 Million Funding Led by Google Inc. Ventures and TPG Biotech PDF Print E-mail
Friday, 14 October 2011 00:29
DNAnexus, a DNA data management and analysis platform, today announced that it has secured $15 million in second-round funding, led by Google Ventures and TPG Biotech. Additional participants in this round of financing include institutional investors First Round Capital, SoftTech VC, K9 Ventures, and Felicis Ventures.
ICF International Awarded $9.7 Million Contract with Centers for Disease Control and Prevention PDF Print E-mail
Thursday, 13 October 2011 00:40
ICF International (NASDAQ:ICFI - News), a leading provider of consulting services and technology solutions to government and commercial clients, has won a re-compete contract with the Centers for Disease Control and Prevention (CDC) to provide data management support and technical assistance to more than 40 CDC-funded grantees. The contract has a value of $9.7 million and a term of one base year and four option years.
Opinion: A Big Pharma Biotech Fund PDF Print E-mail
User Rating :  / 1
Wednesday, 07 March 2012 15:17

Pharmaceutical companies should deploy cash to fund struggling biotech companies, which could generate much needed new drugs.

The biotech industry, one of the US economy’s most innovative sectors, continues to confront massive challenges in raising vital capital for growth.  In addition to threatening the United States’ historical leadership in this area, this mounting problem has important near- and long-term implications for big pharmaceutical companies with pinched R&D budgets struggling to create new drugs, the country’s job growth, and the world’s overall well-being.  However, an effective solution can be devised by creating a Biotech Fund that smartly deploys Big Pharma’s cash to solve the capital crunch of this critical sector of our economy.

Merck & Co., Inc. (MRK) Ditches Bone Drug Deal with Japan Tobacco, Inc. PDF Print E-mail
Thursday, 20 October 2011 00:29
Merck & Co has ended a licensing agreement with Japan Tobacco to develop and market an experimental agent that stimulates bone growth for the treatment of osteoporosis, which the Japanese company said it would now drop from development.
Functional Neuromodulation Inc. Closes $10.4 Million Financing Agreements to Fund Phase II Testing for Potential Alzheimer's Treatment PDF Print E-mail
Wednesday, 19 October 2011 00:16
Functional Neuromodulation Inc, a company advancing deep brain stimulation (DBS) therapies for Alzheimer’s Disease, today announced the closing of $10.4 million in commitments from Genesys Capital and Medtronic, Inc. in its latest round of financing.
Roche Buys Anadys Pharmaceuticals, Inc. (ANDS) for $230 Million to Boost Hepatitis Ops PDF Print E-mail
User Rating :  / 1
Wednesday, 19 October 2011 00:10
Anadys Pharmaceuticals, Inc. /quotes/zigman/92552/quotes/nls/ands ANDS +251.92% today announced that it has entered into a definitive merger agreement to be acquired by Roche (six:RO)(six:ROG)(otcqx:RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share.
Forest Labs looks longterm for next product deals PDF Print E-mail
Tuesday, 18 October 2011 00:54

Forest Laboratories Inc (FRX.N) is looking more at earlier-stage products to acquire rather than more advanced ones because it feels confident it can weather the patent expirations of its two biggest medicines, the drugmaker's finance chief said on Thursday.

Skanska Gets $80 Million Renovation Pact With Merck & Co., Inc. PDF Print E-mail
Monday, 17 October 2011 00:44
Skanska (STO:SKAB) has signed a contract with Merck (NYSE:MRK), known outside of the United States and Canada as MSD, to complete the renovation of a research and development laboratory at Merck's facility in Kenilworth, New Jersey.
GlycoMimetics, Inc. Inks Licensing Deal Worth Up to $340 Million with Pfizer Inc. PDF Print E-mail
Saturday, 15 October 2011 00:47
GlycoMimetics, Inc. announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE:PFE - News) for the GlycoMimetics investigational compound GMI-1070.
Courtagen Life Sciences Completes $8M Offering PDF Print E-mail
Saturday, 15 October 2011 00:42

Courtagen Life Sciences - formerly Avantra Biosciences - has completed an $8 million offering, raising the amount from 67 investors.

The capital adds to a $7 million round completed last year.

AccuDial Pharmaceutical, Inc. Acquires Spinformation/Stephen Key Design, LLC. PDF Print E-mail
Thursday, 13 October 2011 00:43
Accudial Pharmaceutical®, Inc. has acquired Stephen Key Design, LLC. This acquisition expands AccuDial's patent portfolio to over fifty patents for weight based dosing and other extended content rotating labels (ECRL), which adds 75% more labeling space to a container.
£7.6 Million Funding Package Secured for Third Building at Liverpool Science Park; 7,000 Jobs Ahead PDF Print E-mail
Wednesday, 12 October 2011 00:35
The construction of Liverpool Science Park (LSP)’s third building will commence on site next year following the announcement of a £7.6M funding package.
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 26